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In this issue, Wishart et al (2008) address whether ‘screen-detected
breast cancer confers additional prognostic benefit to the patient,
over and above that expected by any shift in stage at presentation’.
Their conclusion is affirmative. Although this observation is not
new and indeed is increasingly understood and accepted by the
research community (Joensuu et al, 2004; Shen et al, 2005), their
study is an important confirmation. One application of the
observation has been in statistical models that make inferences
about the relative contributions of screening and adjuvant therapy
to the decrease in breast cancer mortality that has occurred over
the last 20 years in the United States (and in other countries as
well) (Berry et al, 2005, 2006b; Fryback et al, 2006). A conclusion of
these models is that, taking therapy into account, the observed
breast cancer incidence and mortality would be inconsistent unless
some cancers preferentially detected by screening mammography
had, in the terminology of one study (Fryback et al, 2006), ‘limited
malignant potential’.
Wishart et al (2008) point out a clinical implication: the
relatively good prognosis of screen-detected cancers means that
clinicians are overtreating some patients. Indeed. The problem is
that although we are learning rapidly about the biology of breast
cancer and its impact on treatment (Bazell, 1998; Paik et al, 2004,
2006; Berry et al, 2006a; Hayes et al, 2007), our understanding is
not yet sufficiently advanced to make clear which tumours need
treatment, or which treatments are best for which biological
subtypes. Nor do we know the proportion of patients in either
detection category who will benefit from treatment. Knowing that
fewer screen-detected than symptomatically detected tumours
need treatment is not of much help unless we can identify which
ones they are.
That screen-detected tumours have better prognoses is an
important consideration in clinical research. Method of detection
of breast cancer is not a standard prognostic factor recorded in
clinical trials. This omission is regrettable. In some settings,
method of detection may be as important as lymph node status in
predicting disease recurrence. Happily, the research community is
beginning to recognise this oversight. Trials such as TAILORx in
the United States (Sparano, 2006; National Cancer Institute, 2008;
Sparano and Paik, 2008) have incorporated method of detection on
patient case report forms.
In their analyses of the importance of method of detection,
Wishart et al (2008) correctly adjust for stage of disease and for the
Nottingham Prognostic Index (NPI) more generally. The question
of clinical interest is whether given the clinical, pathological, and
demographic characteristics of the patient and her tumour, it helps
to know the method of detection as well? Their answer is yes.
How can this be? It has always been clear that there is a stage
shift associated with screening mammography: screening tends to
find cancer earlier than otherwise. But it is surprising that a
tumour clinically and pathologically identical to another tumour is
fundamentally different, simply because of the way it was found. A
possible explanation for the additional benefit of screen-detected
tumours is a ‘within-stage shift.’ For example, some node-negative
tumours harbour the potential to become metastatic (or already
are metastatic!) while others do not. But as I discuss below, other
explanations are possible.
The title of the Wishart et al (2008) article is ‘Screen-detected vs
symptomatic breast cancer—is improved survival due to stage
migration alone?’ This could be read as implying that screening
improves survival. In the text they say, ‘Our results confirm a
strong survival advantage of screening compared with sympto-
matic detection’. This is literally and incontrovertibly true. Their
words will be seen by many readers to imply that screening
mammography improves survival. But their study cannot address
the question of screening effectiveness, nor do they claim to
address this question.
There is an inherent aspect of the Wishart et al (2008) study that
makes it difficult to state conclusions without having them
misinterpreted. I speak from experience. There was substantial
press coverage for my observation that method of detection is an
important independent prognostic factor in breast cancer (Shen
et al, 2005). However, despite my protestations, most reporters
interpreted the study as meaning that screening was effective
(which is the reason for the press coverage!). Perhaps my abilities
to explain such matters are limited; after prolonged discussion
with one reporter, she wrote an article with this headline in large
lettering: ‘Mammograms Boost Survival Odds.’ In a nod towards
accuracy, she added a subtitle, in much smaller lettering: ‘The
screenings often detect slower-growing tumours, a new study
finds.’
Wishart et al (2008) make clear that their observation is at least
partially explained by lead-time and length biases. Lead-time bias
is the easier to understand of these two biases. Suppose screening
finds breast cancer an average of 3 years before it would become
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whose tumours are screen-detected and this additional 3 years may
seem to be a benefit. But it is pure bias. Any benefit of screening
has to be above and beyond this 3-year advantage. To get an
unbiased estimate of screening effectiveness in a nonrandomised
setting, one might subtract 3 years from the survival of every
woman whose tumour is detected by screening. The problem is
that in any particular setting we do not know that 3 years is the
right adjustment: the true bias might be larger or smaller.
Length bias is more important than lead-time bias, at least in
breast cancer. But neither its importance nor the concept itself is
easy to understand. ‘Length’ refers to the tumour’s presympto-
matic period when the tumour is mammographically detectable.
The length of this period is the tumour’s sojourn time. Sojourn
time varies from one tumour to another. (There is an obvious
relationship between lead time and sojourn time; lead time is
shorter because it requires actually finding the tumour during the
presymptomatic period.) Sojourn time is typically positive, but it is
negative for tumours that become symptomatic without being
detectable on a mammogram. Breast tumours are heterogeneous,
even after accounting for stage and other known clinical and
biological characteristics. Aggressive tumours have shorter sojourn
times because they grow faster. Indolent tumours have longer
sojourn times. Screening finds tumours in proportion to their
sojourn times, and therefore longer times and slower growing
tumours are preferentially selected. This is length bias. (There are
many analogues: when you look in the sky and see a shooting star,
it is more likely to be one with a longer arc; when you reach into a
newly opened bag of potato chips and select one, it is more likely
to be big.)
A special case of length bias is overdiagnosis, when screening
finds a tumour with a sojourn time so long that the tumour would
not kill the woman even if it was never found.
Again, Wishart et al (2008) make clear that their observation is
at least partially explained by lead-time and length biases. Their
Figure 1 encompasses both, as they understand. Adjusting for NPI
and other factors at least partly removes lead-time bias. But it does
not remove length bias. Some tumours grow slowly. By their very
nature such tumours have better prognoses than do rapidly
growing tumours. Fast growing tumours will eventually become
symptomatic, and among women who participate in screening
mammography programs, they are likely to be the ones detected
symptomatically between screenings (so-called interval cancers).
Some tumours grow so slowly that they would never be detected
were it not for screening. The consequence is overdiagnosis.
Therefore, although the authors are correct in worrying that
screen-detected cancers may be overtreated, a greater concern is
that some screen-detected cancers should never have been detected
in the first place! The rub is that just as with treatment, we do not
yet have a good understanding regarding which cancers we do not
want to detect. Mammography is too crude a tool to make this
distinction.
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